journal
MENU ▼
Read by QxMD icon Read
search

Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology

journal
https://read.qxmd.com/read/30901303/multidisciplinary-care-in-high-risk-prostate-cancer-is-the-new-standard-of-care
#1
Rahul R Parikh, Biren Saraiya
No abstract text is available yet for this article.
March 22, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30901302/randomized-phase-iii-trial-of-ibrutinib-and-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisone-in-non-germinal-center-b-cell-diffuse-large-b-cell-lymphoma
#2
Anas Younes, Laurie H Sehn, Peter Johnson, Pier Luigi Zinzani, Xiaonan Hong, Jun Zhu, Caterina Patti, David Belada, Olga Samoilova, Cheolwon Suh, Sirpa Leppä, Shinya Rai, Mehmet Turgut, Wojciech Jurczak, Matthew C Cheung, Ronit Gurion, Su-Peng Yeh, Andres Lopez-Hernandez, Ulrich Dührsen, Catherine Thieblemont, Carlos Sergio Chiattone, Sriram Balasubramanian, Jodi Carey, Grace Liu, S Martin Shreeve, Steven Sun, Sen Hong Zhuang, Jessica Vermeulen, Louis M Staudt, Wyndham Wilson
PURPOSE: Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated non-germinal center B-cell DLBCL. PATIENTS AND METHODS: Patients were randomly assigned at a one-to-one ratio to ibrutinib (560 mg per day orally) plus R-CHOP or placebo plus R-CHOP. The primary end point was event-free survival (EFS) in the intent-to-treat (ITT) population and the activated B-cell (ABC) DLBCL subgroup...
March 22, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30901301/augmenting-indolent-lymphoma-treatment-options-with-the-combination-of-lenalidomide-and-rituximab
#3
Paul M Barr
No abstract text is available yet for this article.
March 22, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30897038/augment-a-phase-iii-study-of-lenalidomide-plus-rituximab-versus-placebo-plus-rituximab-in-relapsed-or-refractory-indolent-lymphoma
#4
John P Leonard, Marek Trneny, Koji Izutsu, Nathan H Fowler, Xiaonan Hong, Jun Zhu, Huilai Zhang, Fritz Offner, Adriana Scheliga, Grzegorz S Nowakowski, Antonio Pinto, Francesca Re, Laura Maria Fogliatto, Phillip Scheinberg, Ian W Flinn, Claudia Moreira, José Cabeçadas, David Liu, Stacey Kalambakas, Pierre Fustier, Chengqing Wu, John G Gribben
PURPOSE: Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory agent lenalidomide could increase the activity of rituximab. METHODS: A phase III, multicenter, randomized trial of lenalidomide plus rituximab versus placebo plus rituximab was conducted in patients with relapsed and/or refractory follicular or marginal zone lymphoma...
March 21, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30897037/comparison-of-population-based-observational-studies-with-randomized-trials-in-oncology
#5
Payal D Soni, Holly E Hartman, Robert T Dess, Ahmed Abugharib, Steven G Allen, Felix Y Feng, Anthony L Zietman, Reshma Jagsi, Matthew J Schipper, Daniel E Spratt
PURPOSE: Comparative efficacy research performed using population registries can be subject to significant bias. There is an absence of objective data demonstrating factors that can sufficiently reduce bias and provide accurate results. METHODS: MEDLINE was searched from January 2000 to October 2016 for observational studies comparing two treatment regimens for any diagnosis of cancer, using SEER, SEER-Medicare, or the National Cancer Database. Reporting quality and statistical methods were assessed using components of the STROBE criteria...
March 21, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30897036/effectiveness-in-the-absence-of-efficacy-cautionary-tales-from-real-world-evidence
#6
Safiya Karim, Christopher M Booth
No abstract text is available yet for this article.
March 21, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30892989/alk-resistance-mutations-and-efficacy-of-lorlatinib-in-advanced-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer
#7
Alice T Shaw, Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Chia-Chi Lin, Ross A Soo, Gregory J Riely, Sai-Hong Ignatius Ou, Jill S Clancy, Sherry Li, Antonello Abbattista, Holger Thurm, Miyako Satouchi, D Ross Camidge, Steven Kao, Rita Chiari, Shirish M Gadgeel, Enriqueta Felip, Jean-François Martini
PURPOSE: Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity in advanced ALK-positive non-small-cell lung cancer, including in patients who have failed prior ALK TKIs. Molecular determinants of response to lorlatinib have not been established, but preclinical data suggest that ALK resistance mutations may represent a biomarker of response in previously treated patients. PATIENTS AND METHODS: Baseline plasma and tumor tissue samples were collected from 198 patients with ALK-positive non-small-cell lung cancer from the registrational phase II study of lorlatinib...
March 20, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30892988/venetoclax-combined-with-low-dose-cytarabine-for-previously-untreated-patients-with-acute-myeloid-leukemia-results-from-a-phase-ib-ii-study
#8
Andrew H Wei, Stephen A Strickland, Jing-Zhou Hou, Walter Fiedler, Tara L Lin, Roland B Walter, Anoop Enjeti, Ing Soo Tiong, Michael Savona, Sangmin Lee, Brenda Chyla, Relja Popovic, Ahmed Hamed Salem, Suresh Agarwal, Tu Xu, Kaffa M Fakouhi, Rod Humerickhouse, Wan-Jen Hong, John Hayslip, Gail J Roboz
PURPOSE: Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study evaluated the safety and preliminary efficacy of venetoclax, a selective B-cell leukemia/lymphoma-2 inhibitor, together with low-dose cytarabine (LDAC) in older adults with AML. PATIENTS AND METHODS: Adults 60 years or older with previously untreated AML ineligible for intensive chemotherapy were enrolled...
March 20, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30892987/binimetinib-encorafenib-and-cetuximab-triplet-therapy-for-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer-safety-lead-in-results-from-the-phase-iii-beacon-colorectal-cancer-study
#9
Eric Van Cutsem, Sanne Huijberts, Axel Grothey, Rona Yaeger, Pieter-Jan Cuyle, Elena Elez, Marwan Fakih, Clara Montagut, Marc Peeters, Takayuki Yoshino, Harpreet Wasan, Jayesh Desai, Fortunato Ciardiello, Ashwin Gollerkeri, Janna Christy-Bittel, Kati Maharry, Victor Sandor, Jan H M Schellens, Scott Kopetz, Josep Tabernero
PURPOSE: To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial ( ClinicalTrials.gov identifier: NCT02928224; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). PATIENTS AND METHODS: Before initiation of the randomized portion of the BEACON Colorectal Cancer trial, 30 patients with BRAF V600E-mutant mCRC who had experienced treatment failure with one or two prior regimens were to be recruited to a safety lead-in of encorafenib 300 mg daily, binimetinib 45 mg twice daily, plus standard weekly cetuximab...
March 20, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30883247/the-cattle-don-t-care
#10
Stephanie L Graff
No abstract text is available yet for this article.
March 18, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30883246/anticonvulsant-prophylaxis-and-steroid-use-in-adults-with-metastatic-brain-tumors-asco-and-sno-endorsement-of-the-congress-of-neurological-surgeons-guidelines
#11
Susan M Chang, Hans Messersmith, Manmeet Ahluwalia, David Andrews, Priscilla K Brastianos, Laurie E Gaspar, Na Tosha N Gatson, Justin T Jordan, Mustafa Khasraw, Andrew B Lassman, Julia Maues, Maciej Mrugala, Jeffrey Raizer, David Schiff, Glen Stevens, Ashley Sumrall, Martin van den Bent, Michael A Vogelbaum
PURPOSE: The Congress of Neurological Surgeons (CNS) has developed a series of guidelines for the treatment of adults with metastatic brain tumors, including systemic therapy and supportive care topics. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS: Two CNS guidelines were reviewed for developmental rigor by methodologists, and an independent multidisciplinary Expert Panel was formed to review the content and assess agreement with the recommendations...
March 18, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30883245/deleterious-germline-mutations-are-a-risk-factor-for-neoplastic-progression-among-high-risk-individuals-undergoing-pancreatic-surveillance
#12
Toshiya Abe, Amanda L Blackford, Koji Tamura, Madeline Ford, Patrick McCormick, Miguel Chuidian, Jose Alejandro Almario, Michael Borges, Anne Marie Lennon, Eun Ji Shin, Alison P Klein, Ralph H Hruban, Marcia I Canto, Michael Goggins
PURPOSE: To compare the risk of neoplastic progression by germline mutation status versus family history without a known germline mutation (familial risk) among individuals with an increased risk for pancreatic cancer who are undergoing surveillance. METHODS: Of 464 high-risk individuals in the Cancer of the Pancreas Screening program at Johns Hopkins Hospital who were undergoing pancreatic surveillance, 119 had a known deleterious germline mutation in a pancreatic cancer susceptibility gene; 345 met family history criteria for pancreatic surveillance but were not known to harbor a germline mutation...
March 18, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30875281/reply-to-l-xie-et-al
#13
Elizabeth A Mullen, Geetika Khanna, James I Geller, Conrad V Fernandez, Jeffrey S Dome
No abstract text is available yet for this article.
March 15, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30875280/serum-levels-of-microrna-371a-3p-m371-test-as-a-new-biomarker-of-testicular-germ-cell-tumors-results-of-a-prospective-multicentric-study
#14
Klaus-Peter Dieckmann, Arlo Radtke, Lajos Geczi, Cord Matthies, Petra Anheuser, Ulrike Eckardt, Jörg Sommer, Friedemann Zengerling, Emanuela Trenti, Renate Pichler, Hanjo Belz, Stefan Zastrow, Alexander Winter, Sebastian Melchior, Johannes Hammel, Jennifer Kranz, Marius Bolten, Susanne Krege, Björn Haben, Wolfgang Loidl, Christian Guido Ruf, Julia Heinzelbecker, Axel Heidenreich, Jann Frederik Cremers, Christoph Oing, Thomas Hermanns, Christian Daniel Fankhauser, Silke Gillessen, Hermann Reichegger, Richard Cathomas, Martin Pichler, Marcus Hentrich, Klaus Eredics, Anja Lorch, Christian Wülfing, Sven Peine, Werner Wosniok, Carsten Bokemeyer, Gazanfer Belge
PURPOSE: Previous studies suggested that serum levels of microRNA (miR)-371a-3p (so-called M371 test) have a much higher sensitivity and specificity than the classic markers of testicular germ cell tumors (GCTs) and are applicable toward both seminoma and nonseminoma. We sought to confirm the usefulness of this test as a novel biomarker for GCT. PATIENTS AND METHODS: In a prospective, multicentric study, serum samples of 616 patients with testicular GCTs and 258 male controls were examined for serum levels of miRNA-371a-3p (miR levels) by quantitative polymerase chain reaction...
March 15, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30875279/clinical-diagnosis-value-of-chest-x-ray-and-ultrasound-in-recurrence-in-patients-with-favorable-histology-wilms-tumor
#15
Lulu Xie, Baihui Liu, Kuiran Dong
No abstract text is available yet for this article.
March 15, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30875278/neratinib-plus-capecitabine-provides-a-glimmer-of-hope-for-a-daunting-disease
#16
Sara A Hurvitz
No abstract text is available yet for this article.
March 15, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30865549/prospective-multicenter-validation-of-androgen-receptor-splice-variant-7-and-hormone-therapy-resistance-in-high-risk-castration-resistant-prostate-cancer-the-prophecy-study
#17
Andrew J Armstrong, Susan Halabi, Jun Luo, David M Nanus, Paraskevi Giannakakou, Russell Z Szmulewitz, Daniel C Danila, Patrick Healy, Monika Anand, Colin J Rothwell, Julia Rasmussen, Blair Thornburg, William R Berry, Rhonda S Wilder, Changxue Lu, Yan Chen, John L Silberstein, Gabor Kemeny, Giuseppe Galletti, Jason A Somarelli, Santosh Gupta, Simon G Gregory, Howard I Scher, Ryan Dittamore, Scott T Tagawa, Emmanuel S Antonarakis, Daniel J George
PURPOSE: Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which leads to ligand-independent constitutive activation that is not inhibited by anti-androgen therapies, including abiraterone or enzalutamide. Given that previous reports suggested that circulating tumor cell (CTC) AR-V7 detection is a poor prognostic indicator for the clinical efficacy of secondary hormone therapies, we conducted a prospective multicenter validation study. PATIENTS AND METHODS: PROPHECY ( ClinicalTrials...
March 13, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30865548/mutational-analysis-of-patients-with-colorectal-cancer-in-calgb-swog-80405-identifies-new-roles-of-microsatellite-instability-and-tumor-mutational-burden-for-patient-outcome
#18
Federico Innocenti, Fang-Shu Ou, Xueping Qu, Tyler J Zemla, Donna Niedzwiecki, Rachel Tam, Shilpi Mahajan, Richard M Goldberg, Monica M Bertagnolli, Charles D Blanke, Hanna Sanoff, James Atkins, Blasé Polite, Alan P Venook, Heinz-Josef Lenz, Omar Kabbarah
PURPOSE: CALGB/SWOG 80405 was a randomized phase III trial that found no statistically significant difference in overall survival (OS) in patients with first-line metastatic colorectal cancer treated with chemotherapy plus either bevacizumab or cetuximab. Primary tumor DNA from 843 patients has been used to discover genetic markers of OS. PATIENTS AND METHODS: Gene mutations were determined by polymerase chain reaction. Microsatellite status was determined by genotyping of microsatellites...
March 13, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30860950/targeting-stroma-a-tale-of-caution
#19
Andrea Wang-Gillam
No abstract text is available yet for this article.
March 12, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30860949/recist-1-1-for-response-evaluation-apply-not-only-to-chemotherapy-treated-patients-but-also-to-targeted-cancer-agents-a-pooled-database-analysis
#20
Saskia Litière, Gaëlle Isaac, Elisabeth G E De Vries, Jan Bogaerts, Alice Chen, Janet Dancey, Robert Ford, Stephen Gwyther, Otto Hoekstra, Erich Huang, Nancy Lin, Yan Liu, Sumithra Mandrekar, Lawrence H Schwartz, Lalitha Shankar, Patrick Therasse, Lesley Seymour
PURPOSE: The mode of action of targeted cancer agents (TCAs) differs from classic chemotherapy, which leads to concerns about the role of RECIST in evaluating tumor response in trials with TCAs. We investigated the performance of RECIST using a pooled database from 50 clinical trials with at least one TCA. METHODS: We examined the impact of the number of target lesions (TLs) on within-patient variability of tumor response. The prognostic effect of TL response (at 12 weeks or on study on the basis of a maximum five TLs) on survival was studied through landmark and time-dependent Cox models adjusted for baseline tumor load, occurrence of new lesions, or unequivocal progression of nontarget disease...
March 12, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"